Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prochlorperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 7/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 7/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 7/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | HRH1 | P35367 | 7/20 | 1.00 |
| ▸ | DRD3 | P35462 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochlorperazine SCHEMBL14126977 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL29369439 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL18429 | 1.00 | DRD2 (1.00) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL133595 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL2506559 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL1041250 | 0.99 | DRD2 (0.98) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL28086447 | 0.94 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Perphenazine SCHEMBL5307579 | 0.94 | MAPT (0.91) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| Prochlorperazine SCHEMBL10891828 | 0.93 | MAPT (0.90) | DRD2MAPTMAPK1ADRA2AADRA2C | |
| SCHEMBL13485632 | 0.93 | MAPT (0.86) | DRD2MAPTMAPK1ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277636-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITé LAVAL (CA) | 2024-08-22 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4358947-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | UNIVERSITE DE BORDEAUX (FR) | 2024-05-01 | — | — | EP | claimed |
| CN-117897147-A | Combination comprising at least one serotonin reuptake inhibitor and at least one potassium chloride type 2 cotransporter stimulator and medical use thereof | 波尔多大学 | 2024-04-16 | — | — | CN | claimed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| WO-2022268738-A1 | COMBINATION COMPRISING AT LEAST ONE SEROTONIN REUPTAKE INHIBITOR AND AT LEAST ONE STIMULATOR OF POTASSIUM-CHLORIDE COTRANSPORTER TYPE 2 AND ITS MEDICAL USE | Universite de Bordeaux (FR) | 2022-12-29 | — | — | WO | claimed |
| US-12550235-B2 | — | — | 2026-02-10 | — | — | US | disclosed |
| US-20260034303-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | ANTARES PHARMA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2025-12-18 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| EP-4547229-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | Universiteit Gent (BE) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025076082-A1 | PEPTIDE NANOSPONGES FOR DRUG DELIVERY | UNIVERSITY OF KANSAS (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2022219021-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022219021-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-10-20 | — | — | WO | disclosed |
| US-20220330396-A1 | MICROWAVE HEATING UNIT AND METHOD | JT INTERNATIONAL SA (CH) | 2022-10-13 | — | — | US | disclosed |
| WO-2022175673-A1 | PROCHLORPERAZINE FOR USE IN THE TREATMENT OF NEUROBLASTOMA | HEALX LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022173333-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE. LTD. (SG) | 2022-08-18 | — | — | WO | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3747289-B1 | MICROWAVE HEATING UNIT AND METHOD | NVX LABS GMBH (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034303-A1 | Needle Assisted Injection Device Having Reduced Trigger Force | TIMM44, SARAF, TIMM50 | DRD2 2480/4885MAPT 1680/4885MAPK1 1511/4885 |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | DRD2 3763/4885MAPT 3975/4885MAPK1 2477/4885 |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | NPC1L1, NPC1, ABCB4 | DRD2 4816/4885MAPT 2743/4885MAPK1 4537/4885 |
| US-12550235-B2 | — | MTX2, CRY2, MTX1 | DRD2 4116/4885MAPT 883/4885MAPK1 2213/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885MAPT 523/4885MAPK1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.